DCB in de Novo Coronary Lesion

Sponsor:

Collaborators:

Information provided by (Responsible Party):

Liu Bin，Second Hospital of Jilin University

Tracking Information

First Submitted Date ^ICMJE

September 28, 2018

First Posted Date ^ICMJE

October 2, 2018

Last Update Posted Date

October 2, 2018

Actual Study Start Date ^ICMJE

October 2018

Estimated Primary Completion Date

December 2018 (Final data collection date for primary outcome measure)

Current Primary Outcome Measures ^ICMJE

Lumen loss in advanced stage of lesion segments within 3 months[ Time Frame: 3 months ]

Lumen loss in advanced stage of lesion segments within 3 months

Original Primary Outcome Measures ^ICMJE

Same as current

Current Secondary Outcome Measures ^ICMJE

Success rate of interventional therapy (including device success rate, lesion success rate and clinical success rate)[ Time Frame: 3 months ]
Occurrence rate of dissection after procedure[ Time Frame: 3 months ]
Binary restenosis rate 3 months after procedure[ Time Frame: 3 months ]
Cardiovascular clinical composite endpoints related to device at the time of 30 days, 60 days and 90days after the surgery include cardiac death, target vessel myocardial infarction and target lesion revascularization driven by clinical symptoms,[ Time Frame: 3 months ]
Cardiovascular clinical composite endpoints related to patients at the time of 30 days, 60 days and 90 days after the surgery include all-cause mortality, all myocardial infarction and any revascularization[ Time Frame: 3 months ]
ARC-defined occurrence rate of thrombotic events (identified, probable and non-excluded thrombosis during acute, subacute and advanced stage)[ Time Frame: 3 months ]

Descriptive Information

Brief Title ^ICMJE

DCB in de Novo Coronary Lesion

Official Title ^ICMJE

Prospective Clinical Research on Safety and Efficacy of Drug Coated Balloon in de Novo Coronary Lesion With Diameters Larger Than 2.75 mm Under OCT Guidance

Brief Summary

Intro-stent restenosis, bifurcation lesions and small vascular lesion with diameter <2.75mm is the indication of drug coated balloon. In the era of traditional coronary artery balloon dilatation, it is believed that muscle fiber of coronary artery great vessels is more abundant than that of small vessels, and elastic recoil and dissection are easier to appear upon dilatation, which will result in acute vascular occlusion and restenosis, so it is not recommended for great vessels to only receive PTCA therapy. But for patients with good angiography result without combination of serious dissections after predilation, the acute thrombosis seems to be a key factor for acute vascular occlusion. Traditional antiplatelet drug doesn't have a good effect, but the application of new-generation antiplatelet drug (clopidogrel, ticagrelor and tirofiban) has greatly reduced the occurrence rate of acute thrombosis. Therefore, under the guarantee of fully antiplatelet action of new-generation antiplatelet drug, for the patients with good angiography result without combination of serious dissections after predilation, Drug coated balloon seems to be an alternative of the stent. This research is to verify the safety and efficacy of Drug coated balloon in de novo coronary artery lesion with vascular diameter ≥2.75mm.

Detailed Description

Stable or unstable angina patients who accept drug coated balloon dilatation therapy with diameter stenosis≥50%, reference diameter≥2.75mm will be enrolled. OCT examination should be carried out after radiography, predilation, Drug coated balloon dilatation and follow-up. For target lesion, balloon should be used for predilation (the ratio of balloon diameter to vascular diameter being 0.8-1.0:1), and for good predilation effects, high pressure balloon, cutting balloon, dual-wire balloon and spines balloon can be adopted. OCT examination should be carry out after balloon satisfactory predilation. Satisfactory predilation radiography result is residual stenosis≤30%,TIMI 3 flow without major dissections (type C or higher) in NHLBI classification. OCT satisfactory result is residual stenosis≤30% without dissection, or with dissection but the dissection angle is ≤90°. Then carry out DCB balloon dilatation therapy. The ratio of balloon diameter to vascular diameter is 0.8-1.0:1, and both ends of DCB exceed the preprocessing area of lesion for 2-3mm, thus avoiding the occurrence of geographical mismatch. Dilation pressure is 8-10atm, lasting for at least 30s. Each DCB catheter can be used once only.

Study Type ^ICMJE

Interventional

Study Phase

N/A

Study Design ^ICMJE

Allocation:
Intervention Model: Single Group Assignment
Intervention Model Description: Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy
Masking: Interventional
Masking Description:
Primary Purpose: Treatment

Condition ^ICMJE

Intervention ^ICMJE

Device: Drug coated balloon
Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy

Study Arms

Experimental: Drug coated balloon
Patients with de novo lesion whose radiography showed that target lesion diameter stenosis is ≥50%, reference diameter is ≥2.75mm and who agreed with the Drug coated balloon dilatation therapy

Recruitment Information

Recruitment Status ^ICMJE

Not yet recruiting

Estimated Enrollment ^ICMJE

Original Estimated Enrollment ^ICMJE

Same as current

Estimated Study Completion Date

April 2019

Estimated Primary Completion Date

December 2018 (Final data collection date for primary outcome measure)

Eligibility Criteria ^ICMJE

Inclusion Criteria - At the age of 18-80 (18 and 80 included) - The female at reproductive age shouldn't get pregnant or plan to get pregnant during the research - Patients must agree to accept 3-month angiography follow-up - Patients must agree to accept clinical follow-up on 30-day, 60-day and 90-day after operation - Psychologically and linguistically, patients could have an understanding of the research purpose, revealing sufficient compliance with the research proposal. The patients' provision of the informed consent represents that the patient accepts the risks and benefits described in the informed consent. - Target lesion diameter stenosis is ≥50%, and reference vascular diameter is ≥2.75mm - De novo coronary lesion - Type A lesion Exclusion criteria - Patients with myocardial infarction within one week - Patients with congestive heart failure or severe NYHAIV heart failure - Patients with severe valvular heart disease - The female in pregnancy or lactation period - Patients whose life expectancy don't exceed 1 year or who might have difficulty in clinical follow-up - Patients who are of bleeding physique or forbidden to administer anticoagulants or antiplatelet drugs - Patients who suffered from cerebral stroke within 6 months prior to surgery - Patients who are involved in any other clinical trials - Patients who fail to satisfy angiography conditions due to currently suffering from or previously undergoing severe renal failure (GFR<30ml/min) - Patients who underwent heart transplantation - Patients who are deemed inappropriate for inclusion by the researcher due to other reasons - Lesion of left main coronary artery - Double vessel or triple vessel disease needed to be interventional treated - Double vessel or triple vessel disease needed to be interventional treated - Patients who are intolerant of aspirin and/or clopidogrel, have the medical history of neutrocytopenia or thrombocytopenia, or are forbidden to administer clopidogrel due to severe hepatic insufficiency - Patients with known hypersensitivity - Patients with the history of leukopenia (white blood cell count<3x109/L for over 3 days), or neutrocytopenia (ANCs <1,000 neutrophils/mm3 for over 3 days) or thrombocytopenia (blood platelets<100,000/mm3) - Patients having the history of peptic ulcer or gastrointestinal bleeding within the past 6 months

Sex/Gender

Sexes Eligible for Study:

All

Ages

18 Years and older (Adult, Older Adult)

Accepts Healthy Volunteers

Listed Location Countries ^ICMJE

Removed Location Countries

Administrative Information

Has Data Monitoring Committee

U.S. FDA-regulated Product

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No

IPD Sharing Statement

Plan to Share IPD:

Responsible Party

Liu Bin，Second Hospital of Jilin University

Study Sponsor ^ICMJE

Second Hospital of Jilin University

Collaborators ^ICMJE

Investigators ^ICMJE

Principal Investigator: Bin Liu, Doctor Second Hospital of Jilin University

PRS Account

Second Hospital of Jilin University

Verification Date

September 2018

^ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP

请使用微信扫码报名